Cargando…

Genetically Engineered T-Cells for Malignant Glioma: Overcoming the Barriers to Effective Immunotherapy

Malignant gliomas carry a dismal prognosis. Conventional treatment using chemo- and radiotherapy has limited efficacy with adverse events. Therapy with genetically engineered T-cells, such as chimeric antigen receptor (CAR) T-cells, may represent a promising approach to improve patient outcomes owin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chuntova, Pavlina, Downey, Kira M., Hegde, Bindu, Almeida, Neil D., Okada, Hideho
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2019
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6357938/ https://www.ncbi.nlm.nih.gov/pubmed/30740109 http://dx.doi.org/10.3389/fimmu.2018.03062

Ejemplares similares

Correspondence on 'H3.3K27M mutation is not a suitable target for immunotherapy in HLA-A2+ patients with diffuse midline glioma' by Immisch et al
por: Chheda, Zinal S, et al.
Publicado: (2023)

Engineering nanoparticles to overcome barriers to immunotherapy
por: Toy, Randall, et al.
Publicado: (2016)

Inhibition of D-2HG leads to upregulation of a proinflammatory gene signature in a novel HLA-A2/HLA-DR1 transgenic mouse model of IDH1R132H-expressing glioma
por: Chuntova, Pavlina, et al.
Publicado: (2022)

Immune-Checkpoint Blockade and Active Immunotherapy for Glioma
por: Ahn, Brian J., et al.
Publicado: (2013)

Genetic Engineering and Enrichment of Human NK Cells for CAR-Enhanced Immunotherapy of Hematological Malignancies
por: Soldierer, Maren, et al.
Publicado: (2022)

Immunotherapy Approaches in Isocitrate-Dehydrogenase-Mutant Low-Grade Glioma
por: Gallus, Marco, et al.
Publicado: (2023)

Recurrence- and Malignant Progression-Associated Biomarkers in Low-Grade Gliomas and Their Roles in Immunotherapy
por: Teng, Chubei, et al.
Publicado: (2022)

Glioma immunoediting, a driver of tumor evolution, and the next battle for immunotherapy
por: Sonabend, Adam M., et al.
Publicado: (2021)

TIGIT: A promising target to overcome the barrier of immunotherapy in hematological malignancies
por: Jin, Shenhe, et al.
Publicado: (2022)

Combination of Immunotherapy and Radiotherapy for Recurrent Malignant Gliomas: Results From a Prospective Study
por: Jiang, Haihui, et al.
Publicado: (2021)

Novel and shared neoantigen derived from histone 3 variant H3.3K27M mutation for glioma T cell therapy
por: Chheda, Zinal S., et al.
Publicado: (2018)

Editorial: Translation of genetically engineered T cells in cancer immunotherapy
por: Voss, Ralf-Holger, et al.
Publicado: (2023)

Advances in CAR-T Cell Genetic Engineering Strategies to Overcome Hurdles in Solid Tumors Treatment
por: Andrea, Alain E., et al.
Publicado: (2022)

Immunotherapy biomarkers 2016: overcoming the barriers
por: Gulley, James L., et al.
Publicado: (2017)

Overcoming delivery barriers in immunotherapy for glioblastoma
por: Rui, Yuan, et al.
Publicado: (2021)

Barriers to overcoming immunotherapy resistance in glioblastoma
por: Gillette, Julia S., et al.
Publicado: (2023)

Genetic engineering of pigs for xenotransplantation to overcome immune rejection and physiological incompatibilities: The first clinical steps
por: Lei, Tiantian, et al.
Publicado: (2022)

Immunotherapy for malignant glioma
por: Suryadevara, Carter M., et al.
Publicado: (2015)

Immunotherapies for Malignant Glioma
por: Boussiotis, Vassiliki A., et al.
Publicado: (2017)

Deep immune profiling reveals targetable mechanisms of immune evasion in immune checkpoint inhibitor-refractory glioblastoma
por: Simonds, Erin F, et al.
Publicado: (2021)

Targeting Tregs in Malignant Brain Cancer: Overcoming IDO
por: Wainwright, Derek A., et al.
Publicado: (2013)

Overcoming Obstacles in the Development of Antigen-Specific Immunotherapies for Type 1 Diabetes
por: Thomas, Ranjeny, et al.
Publicado: (2021)

Immunotherapy: a promising approach for glioma treatment
por: Yasinjan, Feroza, et al.
Publicado: (2023)

Editorial: Gastrointestinal cancer immunotherapy: from drug resistance mechanisms to overcoming strategies
por: Shi, Tao, et al.
Publicado: (2023)

Spontaneous immune responses against glioma-associated antigens in a long term survivor with malignant glioma
por: Ueda, Ryo, et al.
Publicado: (2007)

Oncolytic Viro-Immunotherapy: An Emerging Option in the Treatment of Gliomas
por: Zeng, Jiayi, et al.
Publicado: (2021)

Deciphering the role of QPCTL in glioma progression and cancer immunotherapy
por: Liu, Yu’e, et al.
Publicado: (2023)

Pre-clinical models for evaluating glioma targeted immunotherapies
por: Frederico, Stephen C., et al.
Publicado: (2023)

Strategies to Overcome Failures in T-Cell Immunotherapies by Targeting PI3K-δ and –γ
por: Chandrasekaran, Sanjay, et al.
Publicado: (2021)

Chimeric antigen receptor engineered NK cellular immunotherapy overcomes the selection of T-cell escape variant cancer cells
por: Lee, Maxwell Y, et al.
Publicado: (2021)

Advances in Immune Microenvironment and Immunotherapy of Isocitrate Dehydrogenase Mutated Glioma
por: Yan, Dongming, et al.
Publicado: (2022)

DDOST Correlated with Malignancies and Immune Microenvironment in Gliomas
por: Chang, Xiaojing, et al.
Publicado: (2022)

Overcoming Resistance to Combination Radiation-Immunotherapy: A Focus on Contributing Pathways Within the Tumor Microenvironment
por: Darragh, Laurel B., et al.
Publicado: (2019)

The New Era of Cancer Immunotherapy: Targeting Myeloid-Derived Suppressor Cells to Overcome Immune Evasion
por: De Cicco, Paola, et al.
Publicado: (2020)

Glioma Stem Cells and Immunotherapy for the Treatment of Malignant Gliomas
por: Toda, Masahiro
Publicado: (2013)

Neoantigens in Hematological Malignancies—Ultimate Targets for Immunotherapy?
por: Roerden, Malte, et al.
Publicado: (2019)

γδ T cells in immunotherapies for B-cell malignancies
por: Rimailho, Léa, et al.
Publicado: (2023)

Functional characterization of TSPAN7 as a novel indicator for immunotherapy in glioma
por: Chen, Long, et al.
Publicado: (2023)

Development of immunotherapy for high-grade gliomas: Overcoming the immunosuppressive tumor microenvironment
por: Franson, Andrea, et al.
Publicado: (2022)

Editorial: The mechanism and novel strategies of overcoming resistance of hematological malignancies to CAR-T cell killing
por: Zhang, Tingting, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_i57entlnll8gjc6m77tpdu7n32